The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 13, 2016
Filed:
Aug. 28, 2014
Bristol-myers Squibb Company, Princeton, NJ (US);
Martin D. Eastgate, Trenton, NJ (US);
Gregory L. Beutner, Green Brook, NJ (US);
Benjamin Cohen, Cranford, NJ (US);
Nicolas Cuniere, Belle Mead, NJ (US);
Lopa V. Desai, Chesterfield, NJ (US);
Monica Fitzgerald, Edison, NJ (US);
Qi Gao, Franklin Park, NJ (US);
Michael Bryan Hay, Scotch Plains, NJ (US);
Michael Joseph Lawler, Mequon, WI (US);
Paul C. Lobben, Lawrenceville, NJ (US);
Christopher S. Regens, San Francisco, CA (US);
Thorsten Rosner, Berkeley Heights, NJ (US);
Neil Strotman, Somerset, NJ (US);
Carolyn S. Wei, Hoboken, NJ (US);
Yi Xiao, Fanwood, NJ (US);
Bin Zheng, Kendall Park, NJ (US);
Keming Zhu, Highland Park, NJ (US);
Bristol-Myers Squibb Company, Princeton, NJ (US);
Abstract
The invention relates to an improved process for synthesizing N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide of the formula: (I) Compound (I) is currently in clinical trials for the treatment of myeloproliferative disorders, such as polycythaemia vera, thrombocythaemia and primary myelofibrosis.